Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Nat Biotechnol. 2019 Mar;37(3):232-237. doi: 10.1038/s41587-019-0042-1. Epub 2019 Feb 18.
The retraction of >30 falsified studies by Anversa et al. has had a disheartening impact on the cardiac cell therapeutics field. The premise of heart muscle regeneration by the transdifferentiation of bone marrow cells or putative adult resident cardiac progenitors has been largely disproven. Over the past 18 years, a generation of physicians and scientists has lost years chasing these studies, and patients have been placed at risk with little scientific grounding. Funding agencies invested hundreds of millions of dollars in irreproducible work, and both academic institutions and the scientific community ignored troubling signals over a decade of questionable work. Our collective retrospective analysis identifies preventable problems at the level of the editorial and peer-review process, funding agencies and academic institutions. This Perspective provides a chronology of the forces that led to this scientific debacle, integrating direct knowledge of the process. We suggest a science-driven path forward that includes multiple novel approaches to the problem of heart muscle regeneration.
安弗萨（Anversa）等人撤回的 30 多篇伪造研究对心脏细胞治疗领域产生了令人沮丧的影响。骨髓细胞或假定的成人驻留心脏祖细胞通过转分化来再生心肌的前提已基本被否定。在过去的 18 年中，一代医生和科学家已经花费了数年时间来研究这些研究，但这些研究没有科学依据，患者面临风险。资助机构投资了数亿美元用于不可复制的工作，学术机构和科学界在十多年的有问题的工作中忽略了令人不安的信号。我们的集体回顾性分析确定了编辑和同行评审过程、资助机构和学术机构层面上可预防的问题。本观点提供了导致这一科学灾难的力量的时间线，整合了对该过程的直接了解。我们建议通过科学驱动的方法向前推进，包括解决心肌再生问题的多种新方法。
